Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Receivables: 2011-2024

Historic Receivables for Lineage Cell Therapeutics (LCTX) over the last 14 years, with Dec 2024 value amounting to $638,000.

  • Lineage Cell Therapeutics' Receivables rose 66.91% to $676,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 21.96%. This contributed to the annual value of $638,000 for FY2024, which is 14.36% down from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Receivables stood at $638,000 for FY2024, which was down 14.36% from $745,000 recorded in FY2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Receivables peaked at $51.4 million during FY2021, and registered a low of $242,000 during FY2020.
  • In the last 3 years, Lineage Cell Therapeutics' Receivables had a median value of $745,000 in 2023 and averaged $754,667.
  • In the last 5 years, Lineage Cell Therapeutics' Receivables crashed by 98.98% in 2020 and then spiked by 21,129.34% in 2021.
  • Yearly analysis of 5 years shows Lineage Cell Therapeutics' Receivables stood at $242,000 in 2020, then skyrocketed by 21,129.34% to $51.4 million in 2021, then crashed by 98.29% to $881,000 in 2022, then decreased by 15.44% to $745,000 in 2023, then fell by 14.36% to $638,000 in 2024.